India Pharma Outlook Team | Monday, 20 April 2026
India is facing a serious thalassemia drug shortage, prompting the government to seek an explanation from Novartis while exploring generic alternatives to stabilize supply.
The issue centers on Desferal, a life-saving treatment used by thalassemia patients to remove excess iron caused by frequent blood transfusions.
Health authorities have stepped in after reports of limited availability in public hospitals, where many patients rely on subsidized care.
Officials have now asked Novartis to clarify the situation, even as the company maintains that there is no overall supply shortage and that the drug remains available in the market. Despite this claim, patients and doctors continue to report difficulty accessing the medicine, especially through government channels.
Also Read: Transforming API & Pharma Manufacturing with Next-Gen EHS Technologies
The growing thalassemia drug shortage has raised concerns about gaps in distribution rather than outright production. Many patients are being forced to turn to private pharmacies, often paying significantly higher prices for a treatment they need regularly to survive. Advocacy groups have flagged that such disruptions can lead to severe health complications if iron levels are not controlled.
In response, the government is actively considering the introduction of generic versions of deferoxamine. Since the drug is off-patent, other manufacturers can legally produce it, which could improve supply and bring down costs. This move is seen as a practical step to reduce dependency on a single supplier and ensure consistent availability across public healthcare facilities.
The situation highlights a broader challenge in India’s healthcare system, where access often depends not just on supply, but on how effectively medicines are distributed to those who need them most.
.jpg)
.jpg)
